Guideline Evolution and Real World Decision Making in EGFR Mutated Metastatic Non-Small Cell Lung Cancer

In this segment, Dr. Devarakonda invites the panel to reflect on how updated clinical guidelines are shaping first line treatment patterns in EGFR mutated metastatic non-small cell lung cancer. Dr. Rotow discusses the strengths and limitations of guideline frameworks, noting that while NCCN recommendations provide a comprehensive roadmap, they often list multiple acceptable options without clear prioritization. This places greater responsibility on clinicians to interpret nuanced trial data and individualize therapy.

The panel highlights that there is growing consensus around the use of combination strategies for many patients, particularly those with high risk features. However, areas of ongoing debate remain, including patient selection for monotherapy versus combination therapy and how to weigh toxicity, comorbidities, and patient preferences. The discussion emphasizes that guidelines inform practice, but real world decision making ultimately requires individualized assessment and shared decision making in EGFR mutated metastatic non-small cell lung cancer.